Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining

Neuropsychopharmacology

Volumn 39, Issue 5, 2014, Pages 1066-1080

  Ares Santos, Sara ^a,b   Granado, Noelia ^a,b,c   Espadas, Isabel ^a,b   Martinez Murillo, Ricardo ^a   Moratalla, Rosario ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

amphetamine derivatives; cell death; neurotoxicity; Parkinson's disease; psychostimulants; silver degeneration stain

Indexed keywords

DOPAMINE; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; BRAIN DEGENERATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; HISTOPATHOLOGY; HYPERTHERMIA; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; MOTOR COORDINATION; MOUSE; NERVE FIBER; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RECTUM TEMPERATURE; SILVER STAINING; SUBSTANTIA NIGRA PARS COMPACTA; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; NECROSIS; NERVE CELL; NERVE DEGENERATION; NERVE TRACT; PATHOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA;

ANIMALS; APOPTOSIS; AXONS; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; NECROSIS; NERVE DEGENERATION; NEURAL PATHWAYS; NEURONS; SILVER STAINING; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84896394999     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.307     Document Type: Article

References (65)

1. Albers DS, Sonsalla PK (1995). Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275: 1104-1114. (Pubitemid 26129911)
2. Ares-Santos S, Granado N, Moratalla R (2013a). Neurobiology of methamphetamine. In: Miller PM (ed) Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders Chapter 57. (Elsevier, Academic Press: San Diego, CA, USA, pp 579-591, ISBN: 9780123983350).
3. Ares-Santos S, Granado N, Moratalla R (2013b). Role of dopamine receptors in the neurotoxicity of methamphetamine. J Intern Med 273: 437-453 (review).
4. Ares-Santos S, Granado N, Oliva I, O'Shea E, Martin ED, Colado MI et al (2012). Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol Dis 45: 810-820.
5. Baquet ZC,Williams D, Brody J, Smeyne RJ (2009). A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161: 1082-1090.
6. Beltramino CA, de Olmos JS, Gallyas F, Heimer L, Záborszky L (1993). Silver staining as a tool for neurotoxic assessment. NIDA Res Monogr 136: 101-126 discussion 126-132 (review).
7. Bowyer JF, Thomas M, Schmued LC, Ali SF (2008). Brain regionspecific neurodegenerative profiles showing the relative importance of amphetamine dose, hyperthermia, seizures, and the blood-brain barrier. Ann N Y Acad Sci 1139: 127-139.
8. Burke RE, O'Malley K (2012). Axon degeneration in Parkinson's disease. Exp Neurol 246: 72-83.
9. Büttner A, Weis S (2006). Neuropathological alterations in drug abusers: the involvement of neurons, glial, and vascular systems. Forensic Sci Med Pathol 2: 115-126. (Pubitemid 44127968)
10. Büttner A (2011). The neuropathology of drug abuse. Neuropathol Appl Neurobiol 37: 118-134 (review).
11. Callaghan RC, Cunningham JK, Sykes J, Kish SJ (2012). Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 120: 35-40.
12. Castro-Blanco S, Encinas JM, Serrano J, Alonso D, Gómez MB, Sánchez J et al (2003). Expression of nitrergic system and protein nitration in adult rat brains submitted to acute hypobaric hypoxia. Nitric Oxide 8: 182-201. (Pubitemid 36765451)
13. Cochiolo JA, Ehsanian R, Bruck DK (2000). Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: evidence of compensatory plasticity in nigrostriatal neurons. J Neurosci Res 59: 126-135. (Pubitemid 30038872)
14. Coleman M (2005). Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6: 889-898 (review). (Pubitemid 41568730)
15. Darmopil S, Mart?́n AB, De Diego IR, Ares S, Moratalla R (2009). Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66: 603-613.
16. Darmopil S, Muñetón-Gómez VC, de Ceballos ML, Bernson M, Moratalla R (2008). Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA. Eur J Neurosci 27: 580-592. (Pubitemid 351239297)
17. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001). Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36: 1-22 (review). (Pubitemid 32763126)
18. de Olmos JS, Beltramino CA, de Olmos de Lorenzo S (1994). Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. Neurotoxicol Teratol 16: 545-561. (Pubitemid 24334048)
19. de Olmos JS, Ebbesson SOE, Heimer L (1981). Silver methods for the impregnation of degenerating axoplasm. In: Heimer L, RoBards MJ (ed). Neuroanatomical Tract-Tracing Methods. Plenum Press: New York, NY, USA, pp 117-170.
20. de Olmos S, Bender C, De Olmos JS, Lorenzo A (2009). Neurodegeneration and prolonged immediate early gene expression throughout cortical areas of the rat brain following acute administration of dizocilpine. Neuroscience 164: 1347-1359.
21. Ernst T, Chang L, Leonido-Yee M, Speck O (2000). Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54: 1344-1349. (Pubitemid 30174057)
22. Espadas I, Darmopil S, Vergaño-Vera E, Ortiz O, Oliva I, Vicario-Abejón C et al (2012). L-DOPA-induced increase in THimmunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol Dis 48: 271-281.
23. Fearnley JM, Lees AJ (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301.
24. Fleckenstein AE, Haughey HM, Metzger RR, Kokoshka JM, Riddle EL, Hanson JE et al (1999). Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol 382: 45-49. (Pubitemid 29518276)
25. Fujikawa DG, Zhao S, Ke X, Shinmei SS, Allen SG (2010). Mild as well as severe insults produce necrotic, not apoptotic, cells: evidence from 60-min seizures. Neurosci Lett 469: 333-337.
26. Granado N, Ares-Santos S, Moratalla R (2013). Methamphetamine and Parkinson's disease. Parkinsons Dis 2013: 308052.
27. Granado N, Ares-Santos S, O'Shea E, Vicario-Abejón C, Colado MI, Moratalla R (2010). Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine. Neurotoxicol Res 18: 48-58.
28. Granado N, Ares-Santos S, Oliva I, O'Shea E, Martin ED, Colado MI et al (2011a). Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis 42: 391-403.
29. Granado N, Escobedo I, O'Shea E, Colado I, Moratalla R (2008a). Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 62: 80-84. (Pubitemid 350156147)
30. Granado N, Lastres-Becker I, Ares-Santos S, Oliva I, Martin E, Cuadrado A et al (2011b). Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia 59: 1850-1863.
31. Granado N, Ortiz O, Suárez LM, Mart?́n ED, Ceña V, Sol?́s JMet al (2008c). D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus. Cereb Cortex 18: 1-12. (Pubitemid 350233047)
32. Granado N, O'Shea E, Bove J, Vila M, Colado MI, Moratalla R (2008b). Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J Neurochem 107: 1102-1112.
33. Halpin LE, Yamamoto BK (2012). Peripheral ammonia as a mediator of methamphetamine neurotoxicity. J Neurosci 32: 13155-13163.
34. Hirata H, Cadet JL (1997). P53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem 69: 780-790. (Pubitemid 27327982)
35. Hotchkiss AJ, Gibb JW (1980). Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 214: 257-262. (Pubitemid 10049032)
36. Kanthasamy K, Gordon R, Jin H, Anantharam V, Ali S, Kanthasamy AG et al (2011). Neuroprotective effect of resveratrol against methamphetamine-induced dopaminergic apoptotic cell death in a cell culture model of neurotoxicity. Curr Neuropharmacol 9: 49-53.
37. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC (1995). Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 18: 527-535 (Review. Erratum in: Trends Neurosci 1996;19:143).
38. Krasnova IN, Cadet JL (2009). Methamphetamine toxicity and messengers of death. Brain Res Rev 60: 379-407. Review.
39. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D (2002). Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 22: 8951-8960. (Pubitemid 35379065)
40. LaVoie MJ, Card JP, Hastings TG (2004). Microglial activation precedes dopamine terminal pathology in methamphetamineinduced neurotoxicity. Exp Neurol 187: 47-57. (Pubitemid 38470011)
41. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998). Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18: 8417-8422. (Pubitemid 28465016)
42. Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE (2000). Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther 295: 1077-1085.
43. Moratalla R, Ares-Santos S, Granado N (2014). Neurotoxicity of methamphetamine. In: Kostrzewa RM (ed) Handbook of Neurotoxicity. Springer: New York, NY, USA, ISBN: 978-1-4614-7458-6 (in press).
44. Ortiz O, Delgado-Garc?́a JM, Espadas I, Bah?́ A, Trullas R, Dreyer JL et al (2010). Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/-mice and in hippocampal siRNA silenced Drd1a mice. J Neurosci 30: 12288-12300.
45. O'Callaghan JP, Miller DB (1994). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270: 741-751. (Pubitemid 24271391)
46. Raff MC, Whitmore AV, Finn JT (2002). Axonal self-destruction and neurodegeneration. Science 296: 868-871.
47. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY (1982). Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235: 93-103. (Pubitemid 12188130)
48. Ricaurte GA, Seiden LS, Schuster CR (1984). Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res 303: 359-364. (Pubitemid 14119385)
49. Ries V, Silva RM, Oo TF, Cheng HC, Rzhetskaya M, Kholodilov N et al (2008). JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. J Neurochem 107: 1578-1588.
50. Rivera A, Cuéllar B, Girón FJ, Grandy DK, de la Calle A, Moratalla R (2002). Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J Neurochem 80: 219-229. (Pubitemid 34809367)
51. Rodrigues TB, Granado N, Ortiz O, Cerdán S, Moratalla R (2007). Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through D(1) dopamine receptors. J Neurosci Res 85: 3284-3293. (Pubitemid 350058516)
52. Rosen GD, Williams RW (2001). Complex trait analysis of the mouse striatum: independent QTLs modulate volume and neuron number. BMC Neurosci 2: 5.
53. Seiden LS, Fischman MW, Schuster CR (1976). Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1: 215-219.
54. Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED (1996). Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res 738: 172-175. (Pubitemid 26379662)
55. Suárez LM, Sol?́s O, Caramés JM, Taravini IR, Sol?́s JM, Murer MG et al (2013). L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry (pii: S0006-3223(13)00416-2) doi:10.1016/j.biopsych.2013.05.006 (e-pub ahead of print 12 June 2013).
56. Sulzer D (2007). Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30: 244-250. (Pubitemid 46667168)
57. Switzer RC III (2000). Application of silver degeneration stains for neurotoxicity testing. Toxicol Pathol 28: 70-83 (review).
58. Todd G, Noyes C, Flavel SC, Della Vedova CB, Spyropoulos P, Chatterton B et al (2013). Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS One 8: e56438.
59. UNODC (2013): World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6)Available at: http://www.unodc. org/unodc/secured/wdr/wdr2013/ World-Drug-Report-2013.pdf.
60. Urrutia A, Rubio-Araiz A, Gutierrez-Lopez MD, ElAli A, Hermann DM, O'Shea E et al (2013). A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine. Neurobiol Dis 50: 49-58.
61. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M et al (2001a). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21: 9414-9418. (Pubitemid 33096884)
62. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D et al (2001b). Association of dopamine transporter reduction with psychomotor impairment in methamphetamineabusers. Am J Psychiatry 158: 377-382. (Pubitemid 32205193)
63. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J (1980). Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181: 151-160. (Pubitemid 10159505)
64. Zhu JP, Xu W, Angulo JA (2006b). Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice. Neuroscience 140: 607-622.
65. Zhu JP, Xu W, Angulo N, Angulo JA (2006a). Methamphetamineinduced striatal apoptosis in the mouse brain: comparison of a binge to an acute bolus drug administration. Neurotoxicology 7: 131-136. (Pubitemid 41745016)